Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Biohaven Ltd. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies across neuroscience, immunology, and oncology. Its core portfolio includes glutamate modulators for neurological disorders, myostatin inhibitors for neuromuscular and metabolic diseases, and Kv7 ion channel activators for epilepsy and mood disorders. Biohaven targets patients with rare and complex conditions, leveraging proprietary drug platforms and clinical expertise to address unmet medical needs globally.
This description was generated via AI from an annual report. Updated about 1 year ago.